Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Nov;34(11):2156–2163. doi: 10.1128/aac.34.11.2156

Evaluation of the anti-influenza virus activities of 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and its sodium salt.

J M Colacino 1, D C DeLong 1, J R Nelson 1, W A Spitzer 1, J Tang 1, F Victor 1, C Y Wu 1
PMCID: PMC172017  PMID: 2073106

Abstract

1,3,4-Thiadiazol-2-ylcyanamide (LY217896) and its sodium salt were shown to be effective against influenza A and B viruses in vitro and in the mouse model. In nondividing confluent MDCK cells, the 50% inhibitory concentration of LY217896 ranged from 0.37 to 1.19 micrograms/ml against various strains of influenza A virus and from 0.75 to 1.54 micrograms/ml against various strains of influenza B virus, with no apparent cytotoxicity. However, at a concentration of 0.31 microgram/ml, LY217896 inhibited the replication of dividing MDCK cells. LY217896 (9 mg/m2 of body surface area per day) administered in the diet, in the drinking water, by oral gavage, by intraperitoneal injection, or by aerosolization was well tolerated and protected CD-1 mice infected with a lethal dose of influenza A or B virus. Effective administration of the compound could be delayed for up to 96 h postinfection. Virus titer was reduced by 1 to 2 log10 units in lungs of mice given LY217896 in the drinking water. Mice treated initially with protective levels of LY217896 were resistant to a subsequent challenge of influenza virus in the absence of the compound, indicating that the animals were able to develop immunity to the initial infection. Administration of LY217896 to uninfected mice did not induce interferon-like activity or interfere with natural killer cell function. In the ferret, LY217896 was effective in preventing fever induced by influenza virus.

Full text

PDF
2156

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aso H., Suzuki F., Ebina T., Ishida N. Antiviral activity of carboxyethylgermanium sesquioxide (Ge-132) in mice infected with influenza virus. J Biol Response Mod. 1989 Apr;8(2):180–189. [PubMed] [Google Scholar]
  2. Belshe R. B., Burk B., Newman F., Cerruti R. L., Sim I. S. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis. 1989 Mar;159(3):430–435. doi: 10.1093/infdis/159.3.430. [DOI] [PubMed] [Google Scholar]
  3. Cohen A., Togo Y., Khakoo R., Waldman R., Sigel M. Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A. J Infect Dis. 1976 Jun;133 (Suppl):A114–A120. doi: 10.1093/infdis/133.supplement_2.a114. [DOI] [PubMed] [Google Scholar]
  4. Dolin R., Reichman R. C., Madore H. P., Maynard R., Linton P. N., Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982 Sep 2;307(10):580–584. doi: 10.1056/NEJM198209023071002. [DOI] [PubMed] [Google Scholar]
  5. Field H. J., Brown G. A. Animal models for antiviral chemotherapy. Antiviral Res. 1989 Nov;12(4):165–180. doi: 10.1016/0166-3542(89)90027-2. [DOI] [PubMed] [Google Scholar]
  6. GRUNERT R. R., MCGAHEN J. W., DAVIES W. L. THE IN VIVO ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE). I. PROPHYLACTIC AND THERAPEUTIC ACTIVITY AGAINST INFLUENZA VIRUSES. Virology. 1965 Jun;26:262–269. doi: 10.1016/0042-6822(65)90273-4. [DOI] [PubMed] [Google Scholar]
  7. HERS J. F., MUDLER J., MASUREL N., vd KUIP L., TYRRELL D. A. Studies on the pathogenesis of influenza virus pneumonia in mice. J Pathol Bacteriol. 1962 Jan;83:207–217. [PubMed] [Google Scholar]
  8. Hall C. B., Dolin R., Gala C. L., Markovitz D. M., Zhang Y. Q., Madore P. H., Disney F. A., Talpey W. B., Green J. L., Francis A. B. Children with influenza A infection: treatment with rimantadine. Pediatrics. 1987 Aug;80(2):275–282. [PubMed] [Google Scholar]
  9. Hayden F. G., Belshe R. B., Clover R. D., Hay A. J., Oakes M. G., Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989 Dec 21;321(25):1696–1702. doi: 10.1056/NEJM198912213212502. [DOI] [PubMed] [Google Scholar]
  10. Hayden F. G., Cote K. M., Douglas R. G., Jr Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother. 1980 May;17(5):865–870. doi: 10.1128/aac.17.5.865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hayden F. G., Rollins B. S., Hay A. J. Anti-influenza virus activity of the compound LY253963. Antiviral Res. 1990 Jul;14(1):25–38. doi: 10.1016/0166-3542(90)90063-d. [DOI] [PubMed] [Google Scholar]
  12. Huffman J. H., Sidwell R. W., Khare G. P., Witkowski J. T., Allen L. B., Robins R. K. In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemother. 1973 Feb;3(2):235–241. doi: 10.1128/aac.3.2.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Magnussen C. R., Douglas R. G., Jr, Betts R. F., Roth F. K., Meagher M. P. Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers. Antimicrob Agents Chemother. 1977 Oct;12(4):498–502. doi: 10.1128/aac.12.4.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Malinoski F., Stollar V. Inhibitors of IMP dehydrogenase prevent sindbis virus replication and reduce GTP levels in Aedes albopictus cells. Virology. 1981 Apr 30;110(2):281–289. doi: 10.1016/0042-6822(81)90060-x. [DOI] [PubMed] [Google Scholar]
  15. Murphy B. R., Chalhub E. G., Nusinoff S. R., Kasel J., Chanock R. M. Temperature-sensitive mutants of influenza virus. 3. Further characterization of the ts-1(E) influenza A recombinant (H3N2) virus in man. J Infect Dis. 1973 Oct;128(4):479–487. doi: 10.1093/infdis/128.4.479. [DOI] [PubMed] [Google Scholar]
  16. Nelson J. A., Rose L. M., Bennett L. L., Jr Mechanism of action of 2-amino-1,3,4-thiadiazole (NSC 4728). Cancer Res. 1977 Jan;37(1):182–187. [PubMed] [Google Scholar]
  17. Ohnishi H., Yamaguchi K., Shimada S., Himuro S., Suzuki Y. Antiviral activity of sodium 5-aminosulfonyl-2,4-dichlorobenzoate (M12325). Antimicrob Agents Chemother. 1982 Aug;22(2):250–254. doi: 10.1128/aac.22.2.250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Oxford J. S. Inhibition of the replication of influenza A and B viruses by a nucleoside analogue (ribavirin). J Gen Virol. 1975 Sep;28(3):409–414. doi: 10.1099/0022-1317-28-3-409. [DOI] [PubMed] [Google Scholar]
  19. Reuman P. D., Keely S., Schiff G. M. Assessment of signs of influenza illness in the ferret model. J Virol Methods. 1989 Apr-May;24(1-2):27–34. doi: 10.1016/0166-0934(89)90004-9. [DOI] [PubMed] [Google Scholar]
  20. Sidwell R. W., Huffman J. H., Khare G. P., Allen L. B., Witkowski J. T., Robins R. K. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972 Aug 25;177(4050):705–706. doi: 10.1126/science.177.4050.705. [DOI] [PubMed] [Google Scholar]
  21. Smith C. B., Charette R. P., Fox J. P., Cooney M. K., Hall C. E. Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection. J Infect Dis. 1980 May;141(5):548–554. doi: 10.1093/infdis/141.5.548. [DOI] [PubMed] [Google Scholar]
  22. Sun C. S., Wilson S. Z., Wyde P. R. Limited efficacy of aerosolized recombinant alpha interferon against virulent influenza A/HK infection in mice. Proc Soc Exp Biol Med. 1986 Feb;181(2):298–304. doi: 10.3181/00379727-181-42257. [DOI] [PubMed] [Google Scholar]
  23. Tang J., DeLong D. C., Marder P., Butler L. D., Ades E. W. Identification of functional subpopulations of murine natural killer cells based on their cell surface asialo GM1 phenotype. Cell Immunol. 1985 Dec;96(2):386–397. doi: 10.1016/0008-8749(85)90369-7. [DOI] [PubMed] [Google Scholar]
  24. Togo Y., McCracken E. A. Double-blind clinical assessment of ribavirin (virazole) in the prevention of induced infection with type B influenza virus. J Infect Dis. 1976 Jun;133 (Suppl):A109–A113. doi: 10.1093/infdis/133.supplement_2.a109. [DOI] [PubMed] [Google Scholar]
  25. Walker J. S., Stephen E. L., Spertzel R. O. Small-particle aerosols of antiviral compounds in treatment of type A influenza pneumonia in mice. J Infect Dis. 1976 Jun;133 (Suppl):A140–A144. doi: 10.1093/infdis/133.supplement_2.a140. [DOI] [PubMed] [Google Scholar]
  26. Wilson S. Z., Knight V., Wyde P. R., Drake S., Couch R. B. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother. 1980 Apr;17(4):642–648. doi: 10.1128/aac.17.4.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Witkowski J. T., Robins R. K., Sidwell R. W., Simon L. N. Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem. 1972 Nov;15(11):1150–1154. doi: 10.1021/jm00281a014. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES